F3 and our team have invested 40 years of research, clinical and pre-clinical trials and studies of Amifostine as a cytoprotectant in support of our new indication, AmiGuard CT. We have a worldwide exclusive license to the intellectual property. More on our story.

With FDA approval, we will introduce AmiGuard CT for CT scans of the chest, pelvis and/or abdomen ordered with and without a contrast agent.

F3 has secured a meaningful IP portfolio to bring the AmiGuard franchise to multiple markets across a broad array of indications that use diverse formulations and are based on strong, pre-existing data.